Haiyan Wen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Haiyan Wen has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Siqi Zhou
Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan 430060, China
3 shared publications- Siqi Zhou
Department of Orthopedics, Renmin Hospital of Wuhan University, China
2 shared publications Chi Ma
Department of Orthopedics, The First Affiliated Hospital of Jishou University, Jishou, Hunan 416000, China
1 shared publicationDonghai Zhao
Jilin medical university, No.5, Jilin street, 132013 Jilin, China
1 shared publicationFei Liao
Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan 430060, China
1 shared publicationFu Lu
1 shared publication
Latest Publications
- Open Access
- 15 October 2026
- Published by Tsinghua University Press in Food Science and Human Wellness
Urolithin A pretreatment protects against seizures through IGF-1R Tyr1166/1167 phosphorylation inhibition and enhances the antiseizure effect of valproic acid
Urolithin A (UA), a metabolite derived from gut microbiota that originates from ellagitannins found in pomegranate, berries, and walnuts, has emerged as a promising postbiotic exhibiting mitophagy-inducing and neuroprotective properties. This study examined the antiseizure effects of UA pretreatment and its potential to enhance the efficacy of valproic acid (VPA), a first-line antiseizure medication, using a pilocarpine-induced status epilepticus (SE) rat model. UA significantly reduced seizure stage, prolonged latency, shortened duration, and decreased incidence of seizures, while alleviating SE-induced behavioral and cognitive impairments. Network pharmacology revealed insulin-like growth factor 1 receptor (IGF-1R) as a critical target of UA. Subsequent experiments demonstrated that UA exerts its therapeutic effects by inhibiting the phosphorylation of IGF-1R. Importantly, the combination of UA and VPA yielded enhanced antiseizure effects compared to either treatment alone in mitigating seizures and behavioral comorbidities. These findings suggest that UA may serve as a valuable adjuvant to conventional antiseizure therapy. Additionally, this study elucidates the antiseizure potential of UA as a pomegranate-derived postbiotic, providing experimental evidence from an animal model to support a UA-VPA combination strategy aimed at improving the efficacy of epilepsy treatment.
- 15 October 2026
- Published by Tsinghua University Press in Food Science and Human Wellness
Open AccessUrolithin A pretreatment protects against seizures through IGF-1R Tyr1166/1167 phosphorylation inhibition and enhances the antiseizure effect of valproic acid
Urolithin A (UA), a metabolite derived from gut microbiota that originates from ellagitannins found in pomegranate, berries, and walnuts, has emerged as a promising postbiotic exhibiting mitophagy-inducing and neuroprotective properties. This study examined the antiseizure effects of UA pretreatment and its potential to enhance the efficacy of valproic acid (VPA), a first-line antiseizure medication, using a pilocarpine-induced status epilepticus (SE) rat model. UA significantly reduced seizure stage, prolonged latency, shortened duration, and decreased incidence of seizures, while alleviating SE-induced behavioral and cognitive impairments. Network pharmacology revealed insulin-like growth factor 1 receptor (IGF-1R) as a critical target of UA. Subsequent experiments demonstrated that UA exerts its therapeutic effects by inhibiting the phosphorylation of IGF-1R. Importantly, the combination of UA and VPA yielded enhanced antiseizure effects compared to either treatment alone in mitigating seizures and behavioral comorbidities. These findings suggest that UA may serve as a valuable adjuvant to conventional antiseizure therapy. Additionally, this study elucidates the antiseizure potential of UA as a pomegranate-derived postbiotic, providing experimental evidence from an animal model to support a UA-VPA combination strategy aimed at improving the efficacy of epilepsy treatment.
- Top Cited Papers
- 7 February 2026
- Published by Elsevier in The Journal of Nutritional Biochemistry
- Vol. 153, 110306
Isoquercitrin attenuates osteoarthritis progression by targeting P53-mediated ferroptosis: A mechanistic study integrating network pharmacology and experimental validation
- 7 February 2026
- Published by Elsevier in The Journal of Nutritional Biochemistry
- Vol. 153, 110306
Top Cited PapersIsoquercitrin attenuates osteoarthritis progression by targeting P53-mediated ferroptosis: A mechanistic study integrating network pharmacology and experimental validation
- 26 February 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 306 (Pt 2) , 141562
Isoquercetin alleviates osteoarthritis via regulating the NOX4/Nrf2 redox imbalance in senescent chondrocytes
- 26 February 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 306 (Pt 2) , 141562
Isoquercetin alleviates osteoarthritis via regulating the NOX4/Nrf2 redox imbalance in senescent chondrocytes
- 9 January 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (7) , 8335-8344
Senkyunolide I prevent chondrocytes from oxidative stress through Nrf2/HO-1 signaling pathway
Osteoarthritis (OA) is a degenerative musculoskeletal disease, featured by the destruction of articular cartilage. Oxidative stress, one of the drivers of the extracellular matrix degradation in cartilage, plays a vital role in OA pathogenesis. Senkyunolide I (SEI) is a natural compound with a prominent anti-oxidative stress property against multiple diseases. However, the protective effect of SEI on OA has not been explored. Here, we aimed to elucidate the effect of SEI on OA in vitro. Our results showed that SEI suppressed the expression of senescence-related markers such as P16 and P21 in IL-1β-induced chondrocytes. Besides, SEI alleviated IL-1β-induced the degradation of extracellular matrix (ECM) by suppressing the matrix proteinase like MMP13 and ATAMDS5 while promoting matrix synthesis regulated biomarkers like COL2A1 and ACAN in chondrocytes. Mechanically, the mitochondrial dysfunction and overproduction of intracellular reactive oxygen species (ROS) in chondrocytes induced by IL-1β were reversed by SEI. Additionally, the ROS inhibitor N-acetylcysteine (NAC) synergistically enhanced the biological effect of SEI in IL-1β-induced chondrocytes. Moreover, it was also found that the expression of Nrf2 and HO-1 was increased by the treatment of SEI in IL-1β-stimulated chondrocytes, while the Nrf2 inhibitor ML385 reversed the protective effect of SEI on OA chondrocytes. In conclusion, SEI could inhibit senescence, the degradation of ECM, and the production of ROS through activating Nrf2/ HO-1 signaling pathway, which provide a novel candidate for OA treatment.
- 9 January 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (7) , 8335-8344
Senkyunolide I prevent chondrocytes from oxidative stress through Nrf2/HO-1 signaling pathway
Osteoarthritis (OA) is a degenerative musculoskeletal disease, featured by the destruction of articular cartilage. Oxidative stress, one of the drivers of the extracellular matrix degradation in cartilage, plays a vital role in OA pathogenesis. Senkyunolide I (SEI) is a natural compound with a prominent anti-oxidative stress property against multiple diseases. However, the protective effect of SEI on OA has not been explored. Here, we aimed to elucidate the effect of SEI on OA in vitro. Our results showed that SEI suppressed the expression of senescence-related markers such as P16 and P21 in IL-1β-induced chondrocytes. Besides, SEI alleviated IL-1β-induced the degradation of extracellular matrix (ECM) by suppressing the matrix proteinase like MMP13 and ATAMDS5 while promoting matrix synthesis regulated biomarkers like COL2A1 and ACAN in chondrocytes. Mechanically, the mitochondrial dysfunction and overproduction of intracellular reactive oxygen species (ROS) in chondrocytes induced by IL-1β were reversed by SEI. Additionally, the ROS inhibitor N-acetylcysteine (NAC) synergistically enhanced the biological effect of SEI in IL-1β-induced chondrocytes. Moreover, it was also found that the expression of Nrf2 and HO-1 was increased by the treatment of SEI in IL-1β-stimulated chondrocytes, while the Nrf2 inhibitor ML385 reversed the protective effect of SEI on OA chondrocytes. In conclusion, SEI could inhibit senescence, the degradation of ECM, and the production of ROS through activating Nrf2/ HO-1 signaling pathway, which provide a novel candidate for OA treatment.
- 15 December 2024
- Published by Springer Nature in British Journal of Cancer
- Vol. 132 (3) , 283-294
Identification of diagnostic biomarkers in prostate cancer-related fatigue by construction of predictive models and experimental validation
Background Cancer-related fatigue (CRF) is a prominent cancer-related complication occurring in Prostate cancer (PCa) patients, profoundly affecting prognosis. The lack of diagnostic criteria and biomarkers hampers the management of CRF. Methods The CRF-related data and PCa single-cell data were retrieved from the GEO database and clinical data was downloaded from the TCGA database. The univariate logistic/Cox regression analysis were used to construct the prediction models. The predictive value of models was analyzed using the ROC curve and Kaplan-Meier survival. The hub genes were screened by an intersection analysis of DEGs. The mice model of PCa and PCa-related fatigue were established, and fatigue-like behaviors of mice were detected. The expression of selected hub genes was validated by RT-PCR and IHC analysis. Results The diagnosis and risk models showed great predictive value both in the training and validation dataset. Five genes (Baiap2l2, Cacng4, Sytl2, Sec31b and Ms4a1) that enriched the CXCL signaling were identified as hub genes. Among all hub genes, the MS4A1 expression is the most significant in PCa-related fatigue mice. Conclusions We identified MS4A1 as a promising biomarker for the diagnosis of PCa-related fatigue. Our findings would lay a foundation for revealing the pathogenesis and developing therapies for PCa-related fatigue.
- 15 December 2024
- Published by Springer Nature in British Journal of Cancer
- Vol. 132 (3) , 283-294
Identification of diagnostic biomarkers in prostate cancer-related fatigue by construction of predictive models and experimental validation
Background Cancer-related fatigue (CRF) is a prominent cancer-related complication occurring in Prostate cancer (PCa) patients, profoundly affecting prognosis. The lack of diagnostic criteria and biomarkers hampers the management of CRF. Methods The CRF-related data and PCa single-cell data were retrieved from the GEO database and clinical data was downloaded from the TCGA database. The univariate logistic/Cox regression analysis were used to construct the prediction models. The predictive value of models was analyzed using the ROC curve and Kaplan-Meier survival. The hub genes were screened by an intersection analysis of DEGs. The mice model of PCa and PCa-related fatigue were established, and fatigue-like behaviors of mice were detected. The expression of selected hub genes was validated by RT-PCR and IHC analysis. Results The diagnosis and risk models showed great predictive value both in the training and validation dataset. Five genes (Baiap2l2, Cacng4, Sytl2, Sec31b and Ms4a1) that enriched the CXCL signaling were identified as hub genes. Among all hub genes, the MS4A1 expression is the most significant in PCa-related fatigue mice. Conclusions We identified MS4A1 as a promising biomarker for the diagnosis of PCa-related fatigue. Our findings would lay a foundation for revealing the pathogenesis and developing therapies for PCa-related fatigue.
- 1 May 2021
- Published by Elsevier in Nutrition Clinique et Métabolisme
- Vol. 35 (2) , 123-128
Oxidative stress-related mitochondrial dysfunction as a possible reason for obese male infertility
- 1 May 2021
- Published by Elsevier in Nutrition Clinique et Métabolisme
- Vol. 35 (2) , 123-128
Oxidative stress-related mitochondrial dysfunction as a possible reason for obese male infertility
- 1 January 2019
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 508 (4) , 1271-1278
Induction of apoptosis by magnolol via the mitochondrial pathway and cell cycle arrest in renal carcinoma cells
- 1 January 2019
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 508 (4) , 1271-1278
Induction of apoptosis by magnolol via the mitochondrial pathway and cell cycle arrest in renal carcinoma cells